Mark J Levis

Professor

1992 …2018
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 5 Similar Profiles
Acute Myeloid Leukemia Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences
Mutation Medicine & Life Sciences
Leukemia Medicine & Life Sciences
fms-Like Tyrosine Kinase 3 Medicine & Life Sciences
4'-N-benzoylstaurosporine Medicine & Life Sciences
Cytarabine Medicine & Life Sciences
Chemotherapy Chemical Compounds

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1992 2018

Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation

Fathi, A. T. , Blonquist, T. M. , Hernandez, D. , Amrein, P. C. , Ballen, K. K. , McMasters, M. , Avigan, D. E. , Joyce, R. , Logan, E. K. , Hobbs, G. , Brunner, A. M. , Joseph, C. , Perry, A. M. , Burke, M. , Behnan, T. , Foster, J. , Bergeron, M. K. , Moran, J. A. , Ramos, A. Y. , Som, T. T. & 6 others Rae, J., Fishman, K. M., McGregor, K. L., Connolly, C., Neuberg, D. S. & Levis, M. J., Jan 15 2018, In : Cancer. 124, 2, p. 306-314 9 p.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Mutation
Maximum Tolerated Dose
3-tyrosine

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3

Nagai, K., Hou, L., Li, L., Nguyen, B., Seale, T., Shirley, C., Ma, H., Levis, M., Ghiaur, G., Duffield, A. & Small, D., Aug 31 2018, In : Oncotarget. 9, 68, p. 32885-32899 15 p.

Research output: Contribution to journalArticle

Protein-Tyrosine Kinases
Leukemia
Acute Myeloid Leukemia
Acute Promyelocytic Leukemia
Ubiquitination

Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity

Lau, B. W., Huh, K., Madero-Marroquin, R., De Marchi, F., Lim, Y., Wang, Q., Lobo, F., Marchionni, L., Smith, D. B., DeZern, A., Levis, M. J., Aplan, P. D., Matsui, W. & Gondek, L. P., Jan 1 2018, (Accepted/In press) In : Oncogene.

Research output: Contribution to journalArticle

Myelodysplastic Syndromes
Granulocyte-Macrophage Progenitor Cells
Gene Expression Profiling
Acute Myeloid Leukemia
Disease Progression

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML

Cortes, J. E., Tallman, M. S., Schiller, G. J., Trone, D., Gammon, G., Goldberg, S. L., Perl, A. E., Marie, J. P., Martinelli, G., Kantarjian, H. M. & Levis, M. J., Aug 9 2018, In : Blood. 132, 6, p. 598-607 10 p.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia
Transplants
Safety
Salvage Therapy
Survival

Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

Cortes, J. , Perl, A. E. , Döhner, H. , Kantarjian, H. , Martinelli, G. , Kovacsovics, T. , Rousselot, P. , Steffen, B. , Dombret, H. , Estey, E. , Strickland, S. , Altman, J. K. , Baldus, C. D. , Burnett, A. , Krämer, A. , Russell, N. , Shah, N. P. , Smith, C. C. , Wang, E. S. , Ifrah, N. & 4 others Gammon, G., Trone, D., Lazzaretto, D. & Levis, M., Jan 1 2018, (Accepted/In press) In : The Lancet Oncology.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia
Protein-Tyrosine Kinases
quizartinib
Therapeutics
Febrile Neutropenia